QUOTE AND NEWS
SeekingAlpha  Jul 22  Comment 
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2014 Earnings Conference Call July 22, 2014 08:30 AM ET Executives Jenna Bosco - Director, IR Sean Power - CFO Mike Weiss - Interim CEO Analysts Joe Pantginis - ROTH Capital Partners ...
Motley Fool  Jul 22  Comment 
TG Therapeutics delivers impressive preliminary phase 1 clinical data for its investigational combo designed to treat blood cancers. Find out why investors are giving this data release a mixed review.
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Adopts+Stockholder+Rights+Plan/9676677.html for the full story.
Benzinga  Jul 2  Comment 
In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00. In the report, MLV & Co noted, “We now raise our PT on TGTX...
Motley Fool  Jun 24  Comment 
TG Therapeutics shares jump after announcing a licensing deal. Find out if this deal makes as much sense as today's pop would imply.
Benzinga  Jun 24  Comment 
Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor...
StreetInsider.com  Jun 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Enters+License+Agreement+for+IRAK4+with+Ligand+%28LGND%29%3B+Will+Get+Stock+%2B+Milestones/9607813.html for the full story.
Motley Fool  Jun 13  Comment 
TG Therapeutics shares nosedive following intriguing clinical data, but quickly rebound. Find out what has investors so confused today.
Benzinga  May 30  Comment 
TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative, clinical-stage biopharmaceutical company today announced clinical results from its ongoing Phase I single agent study of TG-1101 (ublituximab), the Company's novel glycoengineered...
StreetInsider.com  May 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Updates+on+TG-1101+Phase+I+Ahead+of+ASCO/9539047.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki